Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure

被引：0
|
作者：
Jonathan D. Ravid
Luke J. Laffin
机构：
[1] Cleveland Clinic Foundation,Internal Medicine Residency Program
[2] Cleveland Clinic Foundation,Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine
来源：
Current Cardiology Reports | 2022年 / 24卷
关键词：
Finerenone; Mineralocorticoid receptor; Chronic kidney disease (CKD); Hypertension; Albuminuria; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1259
页数：8
相关论文
共 50 条
  • [21] Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
    Ningning Wan
    Asadur Rahman
    Akira Nishiyama
    Journal of Human Hypertension, 2021, 35 : 148 - 156
  • [22] FINERENONE Mineralocorticoid receptor (MR) antagonist Treatment of chronic kidney disease/diabetic nephropathy Treatment of heart failure
    Cole, P.
    DRUGS OF THE FUTURE, 2015, 40 (12) : 801 - 808
  • [23] The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease
    Barrera-Chimal, Jonatan
    Gerarduzzi, Casimiro
    Rossignol, Patrick
    Jaisser, Frederic
    CLINICAL SCIENCE, 2022, 136 (12) : 1005 - 1017
  • [24] Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?
    Huang, Bi
    Mcdowell, Garry
    Rao, Anirudh
    Lip, Gregory Y. H.
    JOURNAL OF HYPERTENSION, 2024, 42 (03) : 396 - 398
  • [25] The non-steroidal mineralocorticoid receptor antagonist finerenone improves left ventricular function in preclinical chronic kidney disease
    Stephan, Y.
    Lima-Posada, I.
    Souille, M.
    Bonnard, B.
    Palacios, R.
    Nicol, L.
    Kolkhof, P.
    Jaisser, F.
    Mulder, P.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2933 - 2933
  • [26] Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
    Kolkhof, Peter
    Delbeck, Martina
    Kretschmer, Axel
    Steinke, Wolfram
    Hartmann, Elke
    Baerfacker, Lars
    Eitner, Frank
    Albrecht-Kuepper, Barbara
    Schaefer, Stefan
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (01) : 69 - 78
  • [27] Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
    Gerisch, Michael
    Heinig, Roland
    Engelen, Anna
    Lang, Dieter
    Kolkhof, Peter
    Radtke, Martin
    Platzek, Johannes
    Lovis, Kai
    Rohde, Gabriele
    Schwarz, Thomas
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (11) : 1546 - 1555
  • [28] The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges (vol 65, pg 1342, 2016)
    Yang, Pingping
    Huang, Tianlun
    Xu, Gaosi
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 82 : 124 - 124
  • [29] Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
    Srikanth Palanisamy
    Mario Funes Hernandez
    Tara I. Chang
    Kenneth W. Mahaffey
    Cardiology and Therapy, 2022, 11 : 337 - 354
  • [30] Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
    Liu, Licette C. Y.
    Schutte, Elise
    Gansevoort, Ron T.
    van der Meer, Peter
    Voors, Adriaan A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (08) : 1123 - 1135
12345